A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
18 years or older at the time of Ph+-CML-CP diagnosis.
Receiving TKI treatment (asciminib, bosutinib, dasatinib, imatinib, or nilotinib) in routine medical care either as initial therapy or after 1 prior TKI therapy.
Receiving treatment at US and US territories (i.e., Puerto Rico) medical practice (e.g. community-based, office-based, hospital-based, academic).
Signed informed consent form (ICF) prior to participation in the study including agreement to be tokenized so that the patient's anonymized RWD (EMRs and/or claims data) can be accessed.
You may not be if
Active participation in an interventional trial that may influence the management of their Ph+-CML-CP disease.
Currently being treated with a CML TKI in 3L or beyond.
Known presence of T315I mutation.
Currently in TFR phase and are not on active CML TKI therapy.
Previously received treatment with a prior stem cell transplant
Pregnant or nursing (lactating) female.
Clareo Health | A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
